Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 82009-0098
Product Overview
NDC 82009-0098 is identified as a biosimilar developed for trastuzumab, marketed under the brand name Herzuma. It is approved by the FDA for treating HER2-positive breast cancer and gastric cancer. As a biosimilar, it competes with the reference product Herceptin (trastuzumab) by Roche.
Market Landscape
Market Size
- The global trastuzumab market reached approximately $7.2 billion in 2022, driven by HER2-positive breast and gastric cancers.
- The U.S. constitutes roughly 40% of the global market, with sales around $2.88 billion in 2022.
- The breast cancer segment accounts for about 70% of trastuzumab sales, with gastric cancers comprising the remaining 30% [1].
Competitive Environment
- Original biologic: Herceptin (Genentech/Roche).
- Biosimilar entrants: Herzuma (celltrion), Kanjinti (Amgen), and others.
- Biosimilars have gained incremental market share since first approval in 2018, with Herzuma capturing an estimated 10-15% of the U.S. trastuzumab market in 2022 [2].
Regulatory and Reimbursement Trends
- The FDA approved Herzuma in early 2019.
- CMS and private payers have started favoring biosimilars to reduce FDA-approved biologics’ expenses.
- Patent cliff for Herceptin expired in 2019, opening the market for biosimilar entry and adoption.
Prescribing Trends
- Adoption accelerates with physician familiarity, insurance coverage adjustments, and clinical guidelines.
- Price premiums for biosimilars are generally 15-30% lower than the reference biologic, influencing market share dynamics.
Price Projections
Current Pricing
- List price for trastuzumab biosimilars, including NDC 82009-0098, ranges between $2,600 and $3,200 per vial.
- The wholesale acquisition cost (WAC) for Herzuma averages around $2,900 per vial (USD) [3].
Projected Price Trends (2023-2028)
- Biosimilar prices are expected to decline 10% annually due to increased competition and manufacturing efficiencies.
- By 2028, the average price per vial could fall to approximately $2,300-$2,500.
- The decline is also driven by payer negotiations, formulary preferences, and volume-based discounts.
| Year |
Expected Price per Vial (USD) |
Remarks |
| 2023 |
$2,900 |
Current market price |
| 2024 |
$2,610 |
10% decline expected |
| 2025 |
$2,350 |
Continuing decline |
| 2026 |
$2,115 |
Market saturation benefits |
| 2027 |
$1,905 |
Cost pressures increase |
| 2028 |
$1,715 |
Steady price reduction |
Market Penetration Impact
- As biosimilar uptake grows, price pressure intensifies, especially with volume discounts and payer incentives.
- Adoption rates projected to reach 25-30% of trastuzumab sales by 2025, potentially reducing prices further.
Revenue Forecasts
Assuming volume growth in line with market penetration:
- Revenues for NDC 82009-0098 could reach $200 million by 2025, with annual growth driven by increased adoption.
- By 2028, revenues could exceed $300 million, assuming stabilized market share and declining prices.
Risks and Opportunities
Risks
- Slow physician adoption due to brand loyalty or safety concerns.
- Payer resistance to price reductions.
- Patent litigation or legal delays affecting market access.
Opportunities
- Increasing awareness and confidence in biosimilars.
- Price reductions creating broader access.
- Expansion into additional indications, such as metastatic gastric cancers.
Key Takeaways
- NDC 82009-0098 (Herzuma) operates within a mature biosimilar market for trastuzumab.
- Market share expansion depends on physician acceptance and payer policies.
- Price declines of approximately 10% annually are forecasted over the next five years.
- Revenues could reach $300 million by 2028, assuming steady adoption and market growth.
- Competitive and legal dynamics remain significant risks.
FAQs
1. How does the price of biosimilar trastuzumab compare to the reference product?
Biosimilars are priced approximately 15-30% lower than Herceptin, with current prices around $2,600 to $3,200 per vial.
2. What factors influence biosimilar adoption in the U.S.?
Physician familiarity, payer formulary policies, brand loyalty, and reimbursement policies predominantly shape adoption.
3. What is the forecasted market share for biosimilars like Herzuma?
Market share is expected to reach 25-30% of trastuzumab sales by 2025.
4. Are biosimilar prices expected to stabilize or continue declining?
Prices are projected to decline steadily, roughly 10% annually, over the next five years.
5. What are the primary risks for biosimilar revenue growth?
Legal challenges, slow market adoption, payer resistance, and potential further biosimilar entrants.
References
- IQVIA, "Global Oncology Market Insights," 2022.
- EvaluatePharma, "Oncology Biosimilar Market Share," 2022.
- Red Book, "Wholesaler Acquisition Cost (WAC) Data," 2023.
